Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2...
Main Authors: | Simpson, CR, Kerr, S, Katikireddi, SV, McCowan, C, Ritchie, LD, Pan, J, Stock, SJ, Rudan, I, Tsang, RSM, de Lusignan, S, Hobbs, FDR, Akbari, A, Lyons, RA, Robertson, C, Sheikh, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2022
|
Similar Items
-
Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Colin R. Simpson, et al.
Published: (2022-08-01) -
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Simpson, CR, et al.
Published: (2021) -
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
by: Agrawal, U, et al.
Published: (2021) -
First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales
by: Kerr, S, et al.
Published: (2022) -
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
by: Joy, M, et al.
Published: (2023)